The receipts

About the field reference

A working reference for peptide protocols. Sources, editorial standard, and disclaimer.

The sources

The field reference, the performance FAQ, and the calculator are built from the following primary sources. The named practitioner appearances are the public record. The primary literature is the peer-reviewed record.

Named practitioner appearances

  • Dr Craig Koniver, MD: Huberman Lab episode, October 2024. Source for the BPC-157 microdose logic, the ipamorelin 100 microgram cap, the 5-on-2-off pattern.
  • Dr Kyle Gillett, MD: Huberman Lab episode on hormone optimisation, plus the 'Tools for Hormone Optimization in Males' episode. Source for the CJC-1295 + ipamorelin stack at 250 to 500 micrograms each.
  • Dr Andy Galpin, PhD: Ask Dr Andy Galpin clips on BPC-157 and PRP. Source for the tumour-risk warning on angiogenic peptides.
  • Dr Peter Attia, MD: Huberman Lab episode on supplements for longevity. Source for the conservative stance on most peptides and the strong endorsement of semaglutide, tirzepatide, and tesamorelin.
  • Andrew Huberman, PhD: Huberman Lab episode on peptide therapeutics, April 2024. Source for the BPC-157 herniated disc story, the sermorelin 3-to-5-nights-a-week pattern, the pinealon REM observation.

Primary literature anchors

  • Sikiric et al.: 30-year programme of BPC-157 work in Zagreb. Current Pharmaceutical Design, 2018.
  • Khavinson laboratory: Epitalon, pinealon, and the Russian peptide bioregulator programme. Multiple papers in Bull Exp Biol Med and Neuro Endocrinol Lett.
  • Pickart: GHK-Cu gene-expression work. J Biomater Sci Polym Ed 2008.
  • Cohen laboratory, USC: MOTS-c, humanin, SHLPs. Cell Metabolism 2015 onwards.
  • King R, Tuthill C: Thymosin alpha-1 comprehensive review. Vitamins & Hormones 2016.
  • Bornstein et al.: Cerebrolysin meta-analysis in stroke. Neurological Sciences 2017.
  • Wilding et al.: STEP 1 trial of semaglutide for weight loss. NEJM 2021.
  • Jastreboff et al.: SURMOUNT-1 trial of tirzepatide. NEJM 2022. Retatrutide phase II 2023.
  • Teichman et al.: CJC-1295 pharmacokinetics. J Clin Endocrinol Metab 2006.

Regulatory anchors

  • FDA Category 2 list (2023): BPC-157 placed on the bulk substances list that prohibits 503A compounding.
  • FDA PCAC 2026 agenda: Pharmacy Compounding Advisory Committee review of BPC-157 and six other peptides, 23 to 24 July 2026.
  • FDA label, Egrifta SV: Tesamorelin approval for HIV lipodystrophy.
  • FDA label, Vyleesi: Bremelanotide approval for hypoactive sexual desire disorder.
  • Therapeutic Goods Administration (Australia, 2023): Public advisory on Melanotan II safety.

The editorial standard

Every dose in the field reference, the FAQ, and the calculator matches across all three. The data file is the source of truth. If you spot a discrepancy, the editorial team will respond to corrections@thepeptideindex.info.

Every claim is sourced. The named practitioner attributions (Koniver, Huberman, Gillett, Galpin, Attia) are from public appearances and are linked in the relevant article. The primary literature citations are listed in each entry.

Every entry carries a one-line plausibility grade: tractable, plausible, speculative, or experimental. The grade is a literal reflection of the human evidence base, not a marketing tag.

Every page carries a last-reviewed date. The site admin gets a 90-day review reminder for any page that has not been touched. The peptide landscape moves fast, and a reference site that does not move with it is worse than no reference at all.

Who this is for

People who want to optimise their biology while they still have a chance to enjoy the upside. Built around the practitioner literature, not the influencer literature. Age-agnostic on purpose. Whether you are 30 and want to recover faster from training, 45 and want to keep the muscle you have, or 65 and want to stay in the race, the protocols and the evidence are the same.

Disclaimer

The Peptide Index is a research reference. It is not medical advice. The dosing figures and protocols in the field reference, the FAQ, and the calculator reflect practitioner consensus, not approved labelling, and not a treatment recommendation.

The site does not sell peptides. The site does not run a clinic. The site does not endorse any specific compounding pharmacy, prescriber, or vendor. The links in the for-prescribers page are to the tools, not to a sales channel.

Work with a prescriber who is willing to monitor bloodwork and who understands your specific medication list. Verify third-party testing (HPLC and mass spectrometry) on any peptide you reconstitute. Source from a US-based 503A or 503B compounding pharmacy with a physician's prescription, or from a clinician who sources from one.